Physician profile
Gregory A Pisel
NPI 1528065604
$852.62
in general payments reported to CMS, 2019-2025
13 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.94 · 2021: $41.80 · 2022: $89.82 · 2023: $192 · 2024: $293 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649 · Education: $47.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.75 |
| Education | $47.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $153.67 | 2022-2025 | Jynarque |
| Travere Therapeutics, INC. | $140.93 | 2023-2025 | Filspari |
| Astrazeneca Pharmaceuticals Lp | $110.88 | 2021-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $84.14 | 2023-2024 | |
| Lilly USA, LLC | $78.34 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $71.97 | 2025 | Tarpeyo |
| Akebia Therapeutics INC | $49.55 | 2019-2024 | Vafseo |
| Ardelyx, INC. | $46.85 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $37.34 | 2022 | |
| Glaxosmithkline, LLC. | $31.23 | 2023 | Benlysta, Jesduvroq |
| Amgen INC. | $18.43 | 2024 | Tavneos |
| Vifor Pharma, INC. | $15.72 | 2023 | Veltassa, Korsuva |
| Nxstage Medical, INC. | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Pisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.